hVIVO Advances hMPV Challenge Model With Successful Pilot Study

Open Orphan Plc ( (GB:HVO) ) just unveiled an update.

hVIVO plc has completed a pilot characterisation study for its human metapneumovirus (hMPV) challenge model, demonstrating strong infection rates and symptomatic responses in healthy volunteers. This successful study supports the development of hMPV vaccines and antivirals, addressing an unmet medical need. The company is now marketing its hMPV challenge model for future trials and aims to collaborate with a partner to finalize the characterisation study. This advancement positions hVIVO at the forefront of efforts to develop preventative measures against hMPV, a virus currently causing significant health concerns in regions like China.

More about Open Orphan Plc

hVIVO plc is a rapidly expanding specialist contract research organisation that leads in testing infectious and respiratory disease vaccines and therapeutics through human challenge clinical trials. The company offers comprehensive early clinical development services to a significant and growing client base, including some of the largest global biopharma companies. Their services encompass an array of human challenge models, specialized drug development, and clinical consultancy services, as well as laboratory testing and clinical field trial services.

YTD Price Performance: -11.71%

Average Trading Volume: 3,010,790

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £123.1M

For detailed information about HVO stock, go to TipRanks’ Stock Analysis page.